Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) closed at $70.11 in the last session, up 0.40% from day before closing price of $69.83. In other words, the price has increased by $0.40 from its previous closing price. On the day, 0.68 million shares were traded. ARWR stock price reached its highest trading level at $71.2965 during the session, while it also had its lowest trading level at $68.0.
Ratios:
We take a closer look at ARWR’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.36 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 60.69. For the most recent quarter (mrq), Quick Ratio is recorded 4.86 and its Current Ratio is at 4.86. In the meantime, Its Debt-to-Equity ratio is 1.57 whereas as Long-Term Debt/Eq ratio is at 1.47.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 19 ’25 when Waddill William D. sold 8,367 shares for $67.65 per share. The transaction valued at 566,038 led to the insider holds 56,563 shares of the business.
Vakiener Victoria sold 10,040 shares of ARWR for $679,491 on Dec 19 ’25. The Director now owns 35,723 shares after completing the transaction at $67.68 per share. On Dec 19 ’25, another insider, Anzalone Christopher Richard, who serves as the Chief Executive Officer of the company, sold 13,445 shares for $67.66 each. As a result, the insider received 909,683 and left with 3,818,512 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 9693237248 and an Enterprise Value of 9375186944. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.48 while its Price-to-Book (P/B) ratio in mrq is 20.41. Its current Enterprise Value per Revenue stands at 11.303 whereas that against EBITDA is 76.674.
Stock Price History:
The Beta on a monthly basis for ARWR is 1.24, which has changed by 2.697785 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, ARWR has reached a high of $72.36, while it has fallen to a 52-week low of $9.57. The 50-Day Moving Average of the stock is 40.06%, while the 200-Day Moving Average is calculated to be 161.29%.
Shares Statistics:
According to the various share statistics, ARWR traded on average about 2.41M shares per day over the past 3-months and 2228210 shares per day over the past 10 days. A total of 135.70M shares are outstanding, with a floating share count of 125.77M. Insiders hold about 7.39% of the company’s shares, while institutions hold 81.10% stake in the company. Shares short for ARWR as of 1765756800 were 10234550 with a Short Ratio of 4.25, compared to 1763078400 on 11596104. Therefore, it implies a Short% of Shares Outstanding of 10234550 and a Short% of Float of 9.7799994.
Earnings Estimates
The dynamic stock of Arrowhead Pharmaceuticals Inc (ARWR) is currently attracting attention from 7.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$1.08, with high estimates of $0.08 and low estimates of -$1.55.
Analysts are recommending an EPS of between -$1.55 and -$5.93 for the fiscal current year, implying an average EPS of -$3.16. EPS for the following year is -$4.53, with 9.0 analysts recommending between -$2.98 and -$6.34.
Revenue Estimates
According to 10 analysts,. The current quarter’s revenue is expected to be $244.84M. It ranges from a high estimate of $425.29M to a low estimate of $9M. As of. The current estimate, Arrowhead Pharmaceuticals Inc’s year-ago sales were $2.5MFor the next quarter, 10 analysts are estimating revenue of $58.94M. There is a high estimate of $209M for the next quarter, whereas the lowest estimate is $1.8M.
A total of 14 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $599.56M, while the lowest revenue estimate was $86M, resulting in an average revenue estimate of $399.8M. In the same quarter a year ago, actual revenue was $829.45MBased on 12 analysts’ estimates, the company’s revenue will be $275.94M in the next fiscal year. The high estimate is $440.1M and the low estimate is $114.2M.
